& Liu, D
Current research is focused on designing drug candidates that would simultaneously address different mechanisms of high glucose in an individual and contribute to satiation, body weight control and patient convenience
Another approved use for Victoza is to reduce the risk of major cardiovascular disease, like heart attack or stroke, in adults with type 2 diabetes with known heart disease
Type 2 diabetes mellitus (DM2) affects a 13.8% of the Spanish population1 and its prevalence is expected to increase in the future.2 The presence of DM2 increases significantly the risk of cardiovascular events, chronic kidney disease (CKD), and premature death3,4 and as its prevalence increases it is expected to rise the incidence of microvascular and macrovascular complications.5 Until the last decade, the control of blood glucose, blood pressure, dyslipidemia, and the use of inhibitors of the renin-angiotensin system (iSRA) have been the only strategies available to reduce cardiovascular and renal risk in this population
After a year of using them, you might lose 12% to 18% more weight than with just lifestyle changes
Published by Obesity, the analysis originated as part of the College of Pharmacys systematic reviews and meta-analysis course
